Chronic kidney disease (CKD) is a growing public health issue. The Centers for Disease Control and Prevention estimates that one in seven Americans, about 35.5 million people, have CKD. A serious form of the disease is antibody-mediated glomerulonephritis (AGN), where antibodies attack the kidney’s glomeruli and cause inflammation and tissue injury.
Researchers reported new results in the Journal of Clinical Investigation Insight using a murine model of AGN. The work was led by Partha Biswas of the Renaissance School of Medicine at Stony Brook University. The team observed immune cells inside the kidney and focused on metabolically reprogrammed neutrophils.
They found that neutrophils in the nephritic kidney increase expression and function of the glucose transporter Glut1. The researchers showed that Glut1 activity in inflammatory cells is necessary for AGN to progress. Disabling Glut1 in neutrophils reduced tissue-damaging effector molecules in both early and late stages, while renal cytokine and chemokine production fell only in the late stage.
Treatment with a Glut1 inhibitor improved kidney pathology in AGN mice. The authors say targeting neutrophil metabolism may be a promising therapeutic strategy for AGN and possibly other forms of CKD. The research was supported in part by the National Institutes of Health.
Difficult words
- glomerulonephritis — inflammation of the kidney's tiny filtering units
- neutrophil — a white blood cell that fights infectionsneutrophils
- reprogram — to change how a cell works or behavesreprogrammed
- glucose transporter — a protein that moves sugar into cells
- inhibitor — a substance that stops or reduces activity
- cytokine — a small protein cells use to send signals
- pathology — damage or disease seen in an organ
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- The authors suggest targeting neutrophil metabolism as a therapy. What do you think are possible benefits or risks of this approach?
- The article says one in seven Americans have CKD. How might this fact affect public health priorities in your community?
- If a treatment improves kidney pathology in mice, what steps do you think are needed before it could be used in people?
Related articles
Lower chemotherapy dose helps people 80+ with lymphoma
A study found that people aged 80 and older with a common lymphoma often do better with a lower chemotherapy dose. Researchers used data from community cancer clinics and say the smaller dose kept effectiveness while reducing side effects.
Exercise better than protein powder for older adults' muscle strength
A clinical trial in people aged 65 and over found that extra protein from whey capsules did not increase muscle strength after 24 weeks. Researchers say resistance exercise remains the most reliable way to improve strength.
AI coach helps medical students learn suturing
Researchers at Johns Hopkins developed an explainable AI tool that gives immediate text feedback to medical students practicing suturing. A small randomized study found faster learning for students with prior experience; beginners showed less benefit.
Wheat fiber protects mice from intestinal inflammation
Two research papers report that adding wheat fiber to the diet protects mice from intestinal inflammation. Gut bacteria release polyphenols from the fiber that reduce inflammation, and authors suggest whole-grain foods may lower IBD risk.
Roads, isolation and more schizophrenia hospital visits
A study in New York City found that neighborhoods isolated by roads and traffic had higher rates of schizophrenia-related hospital visits. The link was independent of traffic-caused air pollution and may reflect social and planning factors.